A long-acting C-natriuretic peptide for achondroplasia

The C-natriuretic peptide (CNP) analog vosoritide has recently been approved for treatment of achondroplasia in children. However, the regimen requires daily subcutaneous injections in pediatric patients over multiple years. The present work sought to develop a long-acting CNP that would provide eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Eric L., Carreras, Christopher W., Reid, Ralph, Ashley, Gary W., Santi, Daniel V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335275/
https://www.ncbi.nlm.nih.gov/pubmed/35858423
http://dx.doi.org/10.1073/pnas.2201067119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335275/
https://www.ncbi.nlm.nih.gov/pubmed/35858423
http://dx.doi.org/10.1073/pnas.2201067119

Ejemplares similares